Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
复制标题
格拉斯哥预后评分可预测接受乐伐替尼治疗的不可切除肝细胞癌患者的生存期：多中心分析
DOI：
10.1097/meg.0000000000002398
复制
发表时间：
2022
影响因子：
2.1
通讯作者：
et al.
中科院分区：
文献类型：
--
作者：
Tada Toshifumi;Kumada Takashi;Hiraoka Atsushi;Hiasa Yoichi;et al.
目的：本研究利用血清c反应蛋白和白蛋白水平计算的格拉斯哥预后评分（GPS）来预测lenvatinib治疗不可切除肝细胞癌（HCC）患者的预后。方法采用lenvatinib治疗Child-Pugh A级HCC患者508例。结果中位总生存期和无进展生存期分别为20.4个月[95%可信区间（CI）， 17.7-23.2个月]和7.5个月（95% CI, 6.8-8.5个月）。GPS评分为0、1和2的患者中位总生存期分别为28.5个月、16.0个月和9.1个月（P< 0.001）。经年龄、性别、运动状态、病因、α-胎蛋白、宏观血管侵犯、肝外扩散、索拉非尼治疗史和GPS校正后，GPS = 1[危险比（HR）， 1.664；95% ci, 1.258-2.201；P< 0.001]和GPS为2 （HR, 2.664; 95% CI, 1.861-3.813； P< 0.001）与总生存率独立相关。GPS评分为0、1和2的患者的中位无进展生存期分别为8.8、6.8和3.8个月（P< 0.001）。当对相同的总生存因素进行调整时，发现GPS为2 （HR, 2.010; 95% CI, 1.452-2.784； P< 0.001）与无进展生存独立相关。随着白蛋白胆红素伴肿瘤淋巴结转移评分的增加，GPS评分为1或2的患者比例增加（P< 0.001）。结论gps可用于预测lenvatinib治疗的不可切除HCC患者的生存。
ObjectiveThe use of Glasgow prognostic score (GPS), calculated using the serum C-reactive protein and albumin levels, to predict the outcomes of patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib was investigated in this study.MethodsA total of 508 patients with Child-Pugh class A HCC treated with lenvatinib were included in this study.ResultsThe median overall and progression-free survivals were 20.4 months [95% confidence interval (CI), 17.7–23.2 months] and 7.5 months (95% CI, 6.8–8.5 months), respectively. The median overall survivals of patients with a GPS of 0, 1, and 2 were 28.5, 16.0, and 9.1 months, respectively (P< 0.001). When adjusted for age, sex, performance status, etiology, α-fetoprotein, macroscopic vascular invasion, extrahepatic spread, history of sorafenib therapy, and GPS, a GPS of 1 [hazard ratio (HR), 1.664; 95% CI, 1.258–2.201; P< 0.001] and a GPS of 2 (HR, 2.664; 95% CI, 1.861–3.813; P< 0.001) were found to be independently associated with overall survival. The median progression-free survivals of patients with a GPS of 0, 1, and 2 were 8.8, 6.8, and 3.8 months, respectively (P< 0.001). When adjusted for the same factors of overall survival, a GPS of 2 (HR, 2.010; 95% CI, 1.452–2.784; P< 0.001) was found to be independently associated with progression-free survival. As the albumin–bilirubin with tumor node metastasis score increased, the proportion of patients with a GPS of 1 or 2 increased (P< 0.001).ConclusionsGPS can be used to predict survival in patients with unresectable HCC who were treated with lenvatinib.
影响因子：
4.1
作者：
Tada, Toshifumi;Kumada, Takashi;Yama, Tsuyoki
通讯作者：
Yama, Tsuyoki
影响因子：
6.7
作者：
Tada, Toshifumi;Kumada, Takashi;Hiasa, Yoichi
通讯作者：
Hiasa, Yoichi
影响因子：
4.2
作者：
Kokudo, Norihiro;Takemura, Nobuyuki;Matsuyama, Yutaka
通讯作者：
Matsuyama, Yutaka